Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Clinical trial NCT06028633 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06028633
Sponsor: Peking University First Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Non-squamous Non-small-cell Lung Cancer Recurrent Non-Squamous Non-Small Cell Lung Cancer Metastatic Non-squamous Non Small Cell Lung Cancer

Start date: 2023-10-01
Primary completion: 2024-10-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.